公开(公告)号：US20140303356A1

公开(公告)日：2014-10-09

申请号：US14353962

申请日：2012-10-26

Applicant: GENMAB A/S

Inventor： Michael Gramer ,  Amitava Kundu ,  Ewald T. J. Van Den Bremer ,  Muriel Van Kamper ,  Patrick Priem ,  Aran Frank Labrijn ,  Joyce I. Meesters ,  Joost J. Neijssen ,  Janine Schuurman ,  Paul Parren ,  Patrick Van Berkel ,  Werner L. Vos ,  Arnout Gerritsen

IPC: C07K1/113 ,  C07K16/46

CPC classification number: C07K1/1133 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/468 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/90

Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.

Abstract translation: 本发明涉及用于生产异二聚体蛋白质的体外方法。

公开(公告)号：US20130095112A1

公开(公告)日：2013-04-18

申请号：US13723816

申请日：2012-12-21

Applicant: Genmab A/S

Inventor： Jens OVERGAARD

IPC: A61K39/395

CPC classification number: A61K39/3955 ,  A61K39/39558 ,  A61K41/0038 ,  A61K2039/545 ,  A61N5/10 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/565 ,  A61K2300/00

Abstract: The invention relates to a method for the treatment of an EGFR-associated tumor comprising administration, to an individual in need thereof, of an anti-EGFR antibody in combination with radiotherapy and a radiosensitising agent. In one embodiment, the treatment further comprises administration of a chemotherapeutic agent.

Abstract translation: 本发明涉及一种治疗EGFR相关肿瘤的方法，包括向有需要的个体施用抗EGFR抗体与放射治疗和放射增敏剂的组合。 在一个实施方案中，治疗还包括施用化学治疗剂。

公开(公告)号：US20250101102A1

公开(公告)日：2025-03-27

申请号：US18833267

申请日：2023-01-27

Applicant: GENMAB A/S

Inventor： Christopher W. L. CHIU ,  Mariana C. STIRNER ,  Minh H. DINH ,  Iliana E. SZAFER-GLUSMAN

IPC: C07K16/28 ,  A61K31/573 ,  A61K39/00 ,  A61P35/00

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone).

公开(公告)号：US20250066507A1

公开(公告)日：2025-02-27

申请号：US18798557

申请日：2024-08-08

Applicant: Genmab A/S

Inventor： Reshma Abdulla RANGWALA ,  Esther C.W. BREIJ ,  Sandra VERPLOEGEN ,  OyewaleV O. ABIDOYE ,  Leonardo Viana NICACIO ,  Anthony CAO ,  Shyra GARDAI

IPC: C07K16/36 ,  A61K45/06 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28

Abstract: The invention provides an anti-PD-1 antibody in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

公开(公告)号：US20250002610A1

公开(公告)日：2025-01-02

申请号：US18755457

申请日：2024-06-26

Applicant: Genmab A/S

Inventor： Bart E.C.G. De Goeij ,  Ilse Jongerius ,  Grietje Andringa ,  Madelon Paauwe ,  Theodorus Sjouuke Plantinga ,  David Satijn ,  Jamila Laoukili ,  Onno Wouter Kranenburg ,  Marije Overdijk

IPC: C07K16/46 ,  A61K39/00 ,  A61P35/04 ,  G01N33/68

Abstract: The present invention relates to a multispecific antibody comprising at least a FAPα binding region comprising a first heavy chain variable region and a first light chain variable region; and a DR4 binding region comprising a second heavy chain variable region and a second light chain variable region. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20240376221A1

公开(公告)日：2024-11-14

申请号：US18660672

申请日：2024-05-10

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Kristel Kemper ,  Maarten van der Kroef ,  Dennis Verzijl ,  Andrea Gorlani ,  Pauline Linda de Goeje ,  Lars Guelen ,  David Satijn ,  Esther C. W. Breij ,  Ugur Sahin ,  Sina Fellermeier-Kopf ,  Maren Köhne

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K16/42

Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20240368297A1

公开(公告)日：2024-11-07

申请号：US18633939

申请日：2024-04-12

Applicant: Genmab A/S

Inventor： Tommy R. LI ,  Craig J. THALHAUSER

IPC: C07K16/28 ,  A61K31/138 ,  A61K31/573 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention provides dosing regimens of bispecific antibodies targeting both CD3 and CD20 when used in the treatment of lymphoma, such as B-cell Non-Hodgkin lymphoma (B-NHL).

公开(公告)号：US12077596B2

公开(公告)日：2024-09-03

申请号：US17360438

申请日：2021-06-28

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil Altintas ,  David Satijn ,  Rik Rademaker ,  Paul Parren ,  Friederike Gieseke ,  Ugur Sahin

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  G01N33/56972 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/92

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US20240262924A1

公开(公告)日：2024-08-08

申请号：US18570257

申请日：2022-06-20

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Ulf FORSSMANN ,  Maria N. JURE-KUNKEL ,  Gaurav BAJAJ ,  Craig THALHAUSER ,  Nora PENCHEVA

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/31

Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer in a subject, comprising administering to the subject a binding agent comprising a first antigen-binding region binding to human CD137, and a second antigen-binding region binding to human PD-L1. The invention further provides a binding agent for use in reducing or preventing progression of a tumor or for use in treatment of cancer.

公开(公告)号：US20240209117A1

公开(公告)日：2024-06-27

申请号：US18507869

申请日：2023-11-13

Applicant: GENMAB A/S

Inventor： Aran Frank LABRIJN ,  Joyce I. MEESTERS ,  Edwald T. J. VAN DER BREMER ,  Joost J. NEIJSSEN ,  Patrick VAN BERKEL ,  Bart DE GOEIJ ,  Tom VINK ,  Jan VAN DE WINKEL ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/46 ,  A61K39/00 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  C07K16/40 ,  G01N33/68

CPC classification number: C07K16/468 ,  C07K16/1063 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/32 ,  C07K16/40 ,  G01N33/6854 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins